The company incurred a loss in its most recent quarterly results.

The clearance in China comes weeks after Pfizer acquired rights to the therapy. Elsewhere, Alnylam is looking for “novel” cardiovascular targets and investors sold off Helus shares.

By Padmanabhan Ananthan March 9 (Reuters) - U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin disease met the main goal in a mid-stage study. Here are some details: * The ...

Right now, Pfizer's dividend payout ratio is above 100%. That suggests the dividend comes with some risk, which is true.

It's entirely possible that Pfizer stock will indeed rebound this year. Perhaps the most likely reason for a bounce is the potential for positive clinical results that excite investors. Many will ...

Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could drive $36–42 upside—read now.

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued S&P 500 Stocks to Buy Right Now. On September 2, Pfizer Inc. (NYSE:PFE) announced a new trial collaboration with Olema Pharmaceuticals for ...

While President Donald Trump announced on Tuesday that Pfizer, one of the leading pharmaceutical companies, had agreed to lower its prices for prescription drugs offered through Medicaid, he also ...

Pfizer's financial results haven't been great in the past couple of years, as its pandemic-related products are no longer the growth drivers they once were. The company will also encounter some ...

Could “TrumpRx” be the prescription for lower drug prices? President Donald Trump announced a landmark deal with Pfizer to cut drug prices and sell medications on TrumpRx, a direct-to-consumer federal ...

Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. Pfizer's financial ...